1. Home
  2. EWTX
  3. EWTX News

Latest Edgewise Therapeutics Inc. (EWTX) News on July 24, 2025

Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
EWTX

TipRanks

a month ago

Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush

EWTX

MT Newswires

a month ago

Wedbush Cuts Price Target on Edgewise Therapeutics to $35 From $40, Keeps Outperform Rating

EWTX

MT Newswires

a month ago

Edgewise Therapeutics Reports 'Positive' 3-Year Becker Data, Phase 2 Duchenne Muscular Dystrophy Findings for Sevasemten

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies
EWTX

PR Newswire

a month ago

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference
EWTX

PR Newswire

2 months ago

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
EWTX

Zacks

2 months ago

All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy

Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
EWTX

Zacks

2 months ago

Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025
EWTX

PR Newswire

2 months ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

EWTX

MT Newswires

3 months ago

RBC Trims Price Target on Edgewise Therapeutics to $48 From $52, Keeps Outperform, Speculative Risk

EWTX

MT Newswires

3 months ago

Wedbush Adjusts Price Target on Edgewise Therapeutics to $40 From $43, Maintains Outperform Rating

EWTX

MT Newswires

3 months ago

Edgewise Therapeutics' Q1 Net Loss Widens; Shares Down Over 3%

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
EWTX

PR Newswire

3 months ago

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
EWTX

Insider Monkey

3 months ago

Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

Why Edgewise Therapeutics Stock Popped This Week
EWTX

Motley Fool

3 months ago

Why Edgewise Therapeutics Stock Popped This Week

EWTX

MT Newswires

3 months ago

Guggenheim Starts Edgewise Therapeutics With Buy Rating, $41 Price Target

Is Edgewise Therapeutics Inc. (NASDAQ:EWTX) the Most Promising Small-Cap Stock According to Analysts?
EWTX

Insider Monkey

3 months ago

Is Edgewise Therapeutics Inc. (NASDAQ:EWTX) the Most Promising Small-Cap Stock According to Analysts?

Bristol Myers stumbles in bid to widen heart drug’s use
EWTX

BioPharma Dive

3 months ago

Bristol Myers stumbles in bid to widen heart drug’s use

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
EWTX

Zacks

3 months ago

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
EWTX

Zacks

3 months ago

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

Edgewise Therapeutics, Inc. (EWTX): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout
EWTX

Insider Monkey

4 months ago

Edgewise Therapeutics, Inc. (EWTX): Among Stocks Insiders Bought in April After Trump’s Tariff Rollout

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
EWTX

Zacks

4 months ago

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Edgewise Therapeutics (EWTX): Among Unstoppable Stocks That Could Double Your Money
EWTX

Insider Monkey

4 months ago

Edgewise Therapeutics (EWTX): Among Unstoppable Stocks That Could Double Your Money

Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial
EWTX

GuruFocus.com

4 months ago

Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial

EWTX

MT Newswires

4 months ago

Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says

EWTX

MT Newswires

4 months ago

Wedbush Adjusts Edgewise Therapeutics Price Target to $43 From $45, Maintains Outperform Rating

EWTX

MT Newswires

4 months ago

RBC Lowers Price Target on Edgewise Therapeutics to $52 From $56, Keeps Outperform, Speculative Risk

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
EWTX

Investor's Business Daily

4 months ago

Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'
EWTX

Investopedia

4 months ago

Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'

EWTX

MT Newswires

4 months ago

Sector Update: Health Care Stocks Fall Pre-Bell Wednesday

EWTX

MT Newswires

4 months ago

Edgewise Therapeutics Reports New Results From Phase 2 Hypertrophic Cardiomyopathy Trial

EWTX

MT Newswires

4 months ago

Edgewise Therapeutics Prices $200 Million Offering

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock
EWTX

PR Newswire

4 months ago

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time
EWTX

PR Newswire

4 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
EWTX

Business Wire

4 months ago

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
EWTX

Business Wire

5 months ago

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

EWTX

MT Newswires

5 months ago

Edgewise Therapeutics Reports Wider-Than-Expected Q4 Net Loss

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
EWTX

Business Wire

5 months ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Should You Invest in Edgewise Therapeutics (EWTX)?
EWTX

Insider Monkey

5 months ago

Should You Invest in Edgewise Therapeutics (EWTX)?

EWTX

MT Newswires

6 months ago

Edgewise Therapeutics Insider Sold Shares Worth $300,300, According to a Recent SEC Filing

EWTX

MT Newswires

6 months ago

Edgewise Therapeutics Insider Sold Shares Worth $287,316, According to a Recent SEC Filing

EWTX

MT Newswires

6 months ago

Edgewise Therapeutics Insider Sold Shares Worth $276,776, According to a Recent SEC Filing

Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now?
EWTX

Insider Monkey

6 months ago

Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now?

EWTX

MT Newswires

6 months ago

Edgewise Therapeutics Names Behrad Derakhshan as COO; Shares Fall

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
EWTX

Business Wire

6 months ago

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

EWTX

MT Newswires

6 months ago

Stifel Nicolaus Initiates Coverage on Edgewise Therapeutics With Hold Rating, $30 Price Target

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans
EWTX

Simply Wall St.

6 months ago

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
EWTX

Business Wire

6 months ago

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
EWTX

Business Wire

7 months ago

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

EWTX

MT Newswires

7 months ago

Edgewise Therapeutics Insider Sold Shares Worth $2,737,470, According to a Recent SEC Filing

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
EWTX

Zacks

7 months ago

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
EWTX

Zacks

7 months ago

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
EWTX

Benzinga

7 months ago

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease

EWTX

MT Newswires

7 months ago

Sector Update: Health Care Stocks Mixed Pre-Bell Monday

EWTX

MT Newswires

7 months ago

Sector Update: Health Care

EWTX

MT Newswires

7 months ago

Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell

Edgewise weighs fast approval path for muscular dystrophy drug
EWTX

BioPharma Dive

7 months ago

Edgewise weighs fast approval path for muscular dystrophy drug

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
EWTX

Business Wire

7 months ago

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

EWTX

MT Newswires

8 months ago

Edgewise Therapeutics Clarifies FDA Warning Unrelated to Clinical Trials, Data

Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
EWTX

Business Wire

8 months ago

Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research

EWTX

MT Newswires

8 months ago

Truist Raises Price Target on Edgewise Therapeutics to $50 From $33, Keeps Buy Rating

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
EWTX

Business Wire

8 months ago

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

EWTX

MT Newswires

9 months ago

RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
EWTX

Business Wire

9 months ago

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now
EWTX

Insider Monkey

10 months ago

Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
EWTX

Business Wire

10 months ago

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
EWTX

BioPharma Dive

10 months ago

Novo sinks on obesity drug results; Sanofi reveals anticipated MS data

EWTX

MT Newswires

10 months ago

RBC Raises Price Target on Edgewise Therapeutics to $42 From $32, Keeps Outperform, Speculative Risk

Company News for Sep 20, 2024
EWTX

Zacks

10 months ago

Company News for Sep 20, 2024

Edgewise’s EDG-7500 shows benefit in two obstructive HCM trials
EWTX

Clinical Trials Arena

10 months ago

Edgewise’s EDG-7500 shows benefit in two obstructive HCM trials

How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease
EWTX

Investor's Business Daily

10 months ago

How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease

EWTX

MT Newswires

10 months ago

Leerink Partners Raises Edgewise Therapeutics' Price Target to $42 From $32, Outperform Rating Maintained

EWTX

MT Newswires

10 months ago

Top Midday Gainers

Why Edgewise Therapeutics Stock Is Up 50% on Thursday
EWTX

Motley Fool

10 months ago

Why Edgewise Therapeutics Stock Is Up 50% on Thursday

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
EWTX

Business Wire

10 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation
EWTX

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
EWTX

Business Wire

a year ago

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

‘Don’t Be Scared of Heights’: J.P. Morgan Suggests 2 Stocks to Buy
EWTX

TipRanks

a year ago

‘Don’t Be Scared of Heights’: J.P. Morgan Suggests 2 Stocks to Buy

Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy
EWTX

Zacks

a year ago

Here's Why Edgewise Therapeutics, Inc. (EWTX) is a Great Momentum Stock to Buy

Three Surprising Names That Could Be On Biogen's Buyout Shortlist
EWTX

Investor's Business Daily

a year ago

Three Surprising Names That Could Be On Biogen's Buyout Shortlist

EWTX

MT Newswires

a year ago

Top Midday Gainers

EWTX

MT Newswires

a year ago

JPMorgan Raises Price Target on Edgewise Therapeutics to $30 From $27, Maintains Overweight Rating

EWTX

GuruFocus.com

a year ago

Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
EWTX

Business Wire

a year ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

EWTX

MT Newswires

a year ago

Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
EWTX

Business Wire

a year ago

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
EWTX

Business Wire

a year ago

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

Edgewise Therapeutics doses first subject in HCM drug trial
EWTX

Clinical Trials Arena

a year ago

Edgewise Therapeutics doses first subject in HCM drug trial

EWTX

MT Newswires

a year ago

Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)
EWTX

Business Wire

a year ago

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

EWTX

MT Newswires

a year ago

Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
EWTX

Business Wire

a year ago

Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
EWTX

Business Wire

a year ago

Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
EWTX

Business Wire

a year ago

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
EWTX

Business Wire

a year ago

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
EWTX

Business Wire

a year ago

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
EWTX

Business Wire

a year ago

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
EWTX

Zacks

a year ago

Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
EWTX

Business Wire

a year ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

13 Best Booming Stocks to Buy Right Now
EWTX

Insider Monkey

a year ago

13 Best Booming Stocks to Buy Right Now

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
EWTX

Business Wire

a year ago

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

Share on Social Networks: